Please provide your email address to receive an email when new articles are posted on . Mineralocorticoid receptor antagonists disrupt the renin-angiotensin-aldosterone system and provide beneficial ...
Steroidal MRAs particularly benefit patients on dialysis, whereas nonsteroidal MRAs help treat patients with nondialysis-dependent CKD. Steroidal mineralocorticoid receptor antagonists (MRAs) reduce ...
Credit: Italfarmaco. The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 EPIDYS study. Duvyzat is the first nonsteroidal treatment approved for patients with ...
Panelists discuss how mineralocorticoid receptor antagonists (MRAs) remain underutilized despite being foundational therapy for heart failure with reduced ejection fraction due to clinician fears of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback